CPhI China 2020 was held successfully in Shanghai, China from Dec. 16th-18th.Sinopeg sent a very professional sales team to participate this exhibition. Our booth Number is W4F21. During the exhibition, many customers visited our booth.  Thanks very much for the support and trust from all friends, customers and partners! We hope we can have close cooperation together, and reach win-win achievement in the future.

CPhI Worldwide 2019 was held successfully in Frankfurt, Germany from Nov. 5th-7th. SINOPEG's CEO Dr. Wengui Weng and sales manager Mr. Lingnan Chen attended this exhibition. Our booth Number is 41K60. We SINOPEG was established in 2011, and specilized in PEG derivatives, PEG block-copolymer, side chain of diabetes medications etc.. We are not only maintain the advantage of old products, but also continue to work on the development of new products.   During the exhibition, many customers visited our booth. We had very deep discusstion with our old customers and partners regarding some issues and problems of ongoing projects, and reached agreements for the further programs. Besides, we also received many new potential customers from all over the world. They showed great interest in our products, and made preliminary cooperation intention with us. Thanks very much for the support and trust from all friends, customers and partners! We hope we can have close cooperation together, and reach win-win achievement in the future.

CPhI China 2019 was held successfully in Shanghai, China from June 18th-20th. We Sinopeg sent a very professional sales team to participate this exhibition. Our booth Number is W4F21. During the exhibition, we had very deep disscuion with old partner, and customers from all over the world came to  consult the company's products，we obtained the approval and praise from our customers. Looking forward to see you again next year, CPhI China 2020 in Shanghai.

Warmly welcome you to visit our booth 1D73 in API  (Hangzhou) from May. 8th to May. 10th, 2019. Exhibition name: the 82nd API China- China international pharmaceutical raw materials, intermediates, packaging, equipment fair. Booth number:1D73 Time: May 8-10,2019 Venue: Hangzhou international expo center We provided a wealth of polyethylene glycol derivatives, side chains of hypoglycemic drugs (Semaglutide side chain, Liraglutide side chain, Insulin Detemir side chain, Insulin Deglutide chain), polyethylene glycol block copolymers, polyethylene glycol phospholipids, etc. Welcome to our booth.

Welcome to visit us at

Recently, SINOPEG's self-developed products, mPEG-DTA-1 and HO-PEG-DTA-5, have been formally granted European patents! This marks the recognition of domestically produced high-end LNP excipients by the international regulatory system, laying a solid foundation for China's innovative drugs to enter the global market! As core components of the LNP delivery system, the structure of PEG lipids decisively influences the safety, stability, and immunogenicity of the formulation. SINOPEG has always been committed to the research and development of new technologies and products, and has already secured a significant position in the field of domestic PEG lipid R&D. The newly authorized mPEG-DTA-1 and HO-PEG-DTA-5 are important achievements of the company's continuous innovation in the PEG lipid field. Innovation Breakthrough: mPEG-DTA-1 and HO-PEG-DTA-5 Granted European Patents HO-PEG-DTA-5 is a PEG lipid containing a hydroxyl terminal, which, together with its structural counterpart mPEG-DTA-1, forms the core layout of SINOPEG's product series in this category. To date, these two products have completed their global intellectual property layout: they obtained Chinese patent authorization back in 2023 (Patent No.: ZL202280003648.7) and recently received European patent authorization. (Screenshot source: European Patent Office, Link: https://register.epo.org/application?number=EP22784092&tab=main) Meanwhile, the independently developed mPEG-DTA-1 has already completed its filing with the CDE (Filing No.: F20230000444) and DMF submission (Filing No.: 039451). Even more encouragingly, HO-PEG-DTA-5 will soon complete dual submissions in China and the US, providing strong excipient support and registration convenience for Chinese innovative pharmaceutical companies aiming for the international mainstream pharmaceutical market! Note: For more product filing information, please feel free to contact us. LNP Technology: A Revolutionary Nano-Delivery Platform Lipid Nanoparticles (LNP), as one of the most successful nano-delivery carriers, have demonstrated exceptional capabilities in delivering cytotoxic chemotherapeutic drugs, antibiotics, and nucleic acid therapeutics. In recent years, with the rapid development of mRNA vaccines and drugs, the importance of LNP technology has become increasingly prominent, making it a focal point in the global pharmaceutical field. The granting of European patents for SINOPEG's products not only reflects the international intellectual property system's recognition of China's innovative achievements but also signifies that Chinese companies are steadily moving towards the center stage in the field of high-end pharmaceutical raw materials, potentially injecting new vitality into the global development of LNP technology. Product Portfolio: Extensive Layout Meets Diverse Needs Leveraging profound technical expertise, SINOPEG has developed a variety of novel PEG-lipid structures, providing more high-quality options for glo...